Cargando…

A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers

Long noncoding RNAs are emerging players in the epigenetic machinery with key roles in development and diseases. Here we uncover a complex network comprising a promoter-associated noncoding RNA (paRNA), microRNA and epigenetic regulators that controls transcription of the tumour suppressor E-cadheri...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisignano, Giuseppina, Napoli, Sara, Magistri, Marco, Mapelli, Sarah N., Pastori, Chiara, Di Marco, Stefano, Civenni, Gianluca, Albino, Domenico, Enriquez, Claudia, Allegrini, Sara, Mitra, Abhishek, D'Ambrosio, Gioacchino, Mello-Grand, Maurizia, Chiorino, Giovanna, Garcia-Escudero, Ramon, Varani, Gabriele, Carbone, Giuseppina M., Catapano, Carlo V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459991/
https://www.ncbi.nlm.nih.gov/pubmed/28555645
http://dx.doi.org/10.1038/ncomms15622
Descripción
Sumario:Long noncoding RNAs are emerging players in the epigenetic machinery with key roles in development and diseases. Here we uncover a complex network comprising a promoter-associated noncoding RNA (paRNA), microRNA and epigenetic regulators that controls transcription of the tumour suppressor E-cadherin in epithelial cancers. E-cadherin silencing relies on the formation of a complex between the paRNA and microRNA-guided Argonaute 1 that, together, recruit SUV39H1 and induce repressive chromatin modifications in the gene promoter. A single nucleotide polymorphism (rs16260) linked to increased cancer risk alters the secondary structure of the paRNA, with the risk allele facilitating the assembly of the microRNA-guided Argonaute 1 complex and gene silencing. Collectively, these data demonstrate the role of a paRNA in E-cadherin regulation and the impact of a noncoding genetic variant on its function. Deregulation of paRNA-based epigenetic networks may contribute to cancer and other diseases making them promising targets for drug discovery.